Ceiling effect for respiratory depression by nalbuphine

Area of Science:

• Pharmacology
• Anesthesiology
• Respiratory Medicine

Background:

• Nalbuphine is a potent analgesic with narcotic antagonist properties.
• Morphine is a commonly used potent analgesic for pain management.
• Respiratory depression is a significant side effect of potent analgesics.

Purpose of the Study:

• To compare the respiratory depressant effects of nalbuphine and morphine.
• To investigate the dose-response relationship of nalbuphine-induced respiratory depression.
• To identify potential safety advantages of nalbuphine over morphine.

Main Methods:

• A steady-state method using CO2 response displacement was employed to measure respiratory depression.
• Equianalgesic doses of nalbuphine and morphine were administered to healthy subjects.
• Dose-escalation studies were conducted to determine the maximum respiratory depressant effect.

Main Results:

• At equianalgesic doses, nalbuphine and morphine caused similar respiratory depression.
• Nalbuphine demonstrated a flatter dose-effect curve for respiratory depression compared to morphine.
• A ceiling effect for respiratory depression was observed with nalbuphine at doses above 30 mg/70 kg.
• Subjective effects of nalbuphine were milder than morphine, with fewer psychotomimetic side effects.

Conclusions:

• Nalbuphine exhibits a ceiling effect for respiratory depression, a safety feature not seen with morphine.
• This ceiling effect suggests a potentially wider safety margin for nalbuphine compared to morphine.
• Nalbuphine's respiratory depression can be effectively antagonized by naloxone, nalorphine, and levallorphan.